Incorporation of silicon into strontium modified calcium phosphate bone cements promotes osteoclastogenesis of human peripheral mononuclear blood cells.
Given the important effects of strontium and silicon on cells of the bone as well as the increasing incidence of osteoporotic fractures, calcium phosphate-based bone cements containing silicon and strontium might represent a promising tool for bone replacement therapies of systemically altered bone. However, information about combined effects of strontium and silicon on osteoclastogenesis is still not available. Therefore, differentiation capacity of human peripheral blood mononuclear cells into osteoclast-like cells was investigated by culturing the cells in combination with a strontium- (pS100) and a strontium/silicon-modified calcium phosphate bone cement (pS100-G). Following culturing expression patterns of the cells in respect of their differentiation- and fusion-capacity were determined by real-time quantitative polymerase chain reaction, while cell morphology was visualized by phalloidin staining of the actin cytoskeleton. Additionally, strontium and silicon release from the bone cements into the cultivation media was determined using inductively coupled plasma mass spectrometry while surface topography of the cements was investigated by scanning electron microscopy. The results show that simultaneous incorporation of strontium and silicon into calcium phosphate cements changes properties of the cement such as solubility, and nearly abrogates the inhibitory effects of strontium on osteoclastogenesis.